These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 9778749)

  • 1. Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein.
    Michon F; Fusco PC; Minetti CA; Laude-Sharp M; Uitz C; Huang CH; D'Ambra AJ; Moore S; Remeta DP; Heron I; Blake MS
    Vaccine; 1998 Nov; 16(18):1732-41. PubMed ID: 9778749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
    Lin H; Peng Y; Lin Z; Zhang S; Guo Y
    Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies.
    Choi EH; Zhang F; Lu YJ; Malley R
    Clin Vaccine Immunol; 2016 Feb; 23(2):162-7. PubMed ID: 26677201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media.
    Giebink GS; Koskela M; Vella PP; Harris M; Le CT
    J Infect Dis; 1993 Feb; 167(2):347-55. PubMed ID: 8421168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
    Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
    Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model.
    Park C; Kwon EY; Choi SM; Cho SY; Byun JH; Park JY; Lee DG; Kang JH; Shin J; Kim H
    Hum Vaccin Immunother; 2017 May; 13(5):1169-1176. PubMed ID: 27960627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model.
    Giebink GS; Meier JD; Quartey MK; Liebeler CL; Le CT
    J Infect Dis; 1996 Jan; 173(1):119-27. PubMed ID: 8537648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Infect Immun; 2001 Jan; 69(1):297-306. PubMed ID: 11119518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
    Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
    J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
    Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
    Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines.
    Fattom A; Cho YH; Chu C; Fuller S; Fries L; Naso R
    Vaccine; 1999 Jan; 17(2):126-33. PubMed ID: 9987146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies.
    Chu RS; McCool T; Greenspan NS; Schreiber JR; Harding CV
    Infect Immun; 2000 Mar; 68(3):1450-6. PubMed ID: 10678959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics.
    Steinhoff MC; Edwards K; Keyserling H; Thoms ML; Johnson C; Madore D; Hogerman D
    Pediatr Infect Dis J; 1994 May; 13(5):368-72. PubMed ID: 8072818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity.
    McCool TL; Harding CV; Greenspan NS; Schreiber JR
    Infect Immun; 1999 Sep; 67(9):4862-9. PubMed ID: 10456942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotype of Streptococcus pneumoniae capsular polysaccharide can modify the Th1/Th2 cytokine profile and IgG subclass response to pneumococal-CRM(197) conjugate vaccines in a murine model.
    Mawas F; Feavers IM; Corbel MJ
    Vaccine; 2000 Dec; 19(9-10):1159-66. PubMed ID: 11137252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of infant mice from challenge with Streptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide--pneumolysoid conjugate.
    Lee CJ; Lock RA; Andrew PW; Mitchell TJ; Hansman D; Paton JC
    Vaccine; 1994 Aug; 12(10):875-8. PubMed ID: 7975828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.